Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF in HIV-1 Infected Subjects on Antiretroviral Therapy
NCT00000850Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing GM-CSF Arm with Placebo Arm (2 arms). Primary endpoints: Plasma HIV-1 RNA at 52 weeks and CD4 Cell Count at 52 weeks. Status: completed.
02
Drugs
sargramostim
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00000850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000850.